Arcturus Therapeutics Holdings (ARCT) Receivables (2018 - 2026)

Arcturus Therapeutics Holdings' Receivables history runs 9 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• Quarterly Receivables fell 90.78% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 90.78% YoY) and the FY2025 annual result came in at $9.2 million, up 41.62% from the prior year.
• Receivables was $1.3 million for Q1 2026 at Arcturus Therapeutics Holdings, down from $9.2 million in the prior quarter.
• Across five years, Receivables topped out at $92.5 million in Q1 2023 and bottomed at $1.3 million in Q1 2026.
• A 5-year average of $18.5 million and a median of $9.2 million in 2025 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables jumped 2405.64% — and 2026, when it plunged 90.78%.
• Arcturus Therapeutics Holdings' Receivables stood at $2.8 million in 2022, then jumped by 1060.06% to $32.1 million in 2023, then slumped by 79.8% to $6.5 million in 2024, then jumped by 41.62% to $9.2 million in 2025, then plunged by 85.36% to $1.3 million in 2026.
• Business Quant data shows ARCT's Receivables at $1.3 million in Q1 2026, $9.2 million in Q4 2025, and $8.0 million in Q3 2025.